Skip to main content
. 2016 Sep 16;7(45):73754–73768. doi: 10.18632/oncotarget.12062

Figure 6. MB109 suppresses Hep3B cell growth and LCSC population in mouse xenograft model.

Figure 6

A. Time course analysis of tumor growth. MB109 was injected at 250 intraperitoneally (left panel), or 1000 μg/kg intravenously (right panel). Inhibition of tumor growth was observed in both experimental groups. Red arrows indicate the three time points of injection. The results are shown in means±SD (Sham, n=5; MB109-IP250, n=6; MB109-IV1000, n=4-5, one mouse was dead at day 8). B. IHC analysis of xenograft tumor from sham and MB109-IP250 group. Paraffin sectioned tissues were stained with proliferation marker Ki67/DAB (brown) and counterstained with hematoxylin (purple). C. No difference of the body weight was observed among the mice groups. D. Immuno-fluorescence images show that the expression of CD44 on the xenografted tumor tissue of the MB109-IP250 group was reduced as compared to that of the Sham group. CD44 antibodies were conjugated with FITC. Tumor tissues were nuclear counter stained with DAPI (left panel). CD44+ populations from the tumors were compared using FACScan (right panel). Immunohistochemistry images show that the expression of CD90 E. and AFP F. on the xenografted tumor tissue of the MB109-IP250 group was reduced as compared to that of the Sham group. Antibody bound regions of CD90 and AFP were visualized with DAB and counter stained with hematoxylin.